Aleti R, Murthy KVR. Development and validation of UV spectroscopic method for estimation of sacubitril and valsartan combination (LCZ696) in bulk and pharmaceutical tablet dosage forms. Res J Pharm Technol, 2022; 15(11):5232-8. https://doi.org/10.52711/0974-360X.2022.00881 |
|
Ayalasomayajula S, Langenickel T, Pal P, Boggarapu S, Sunkara G. Clinical pharmacokinetics of sacubitril/valsartan (LCZ696): a novel angiotensin receptor-neprilysin inhibitor. Clin Pharmacokinet, 2017; 56(12):1461-78. https://doi.org/10.1007/s40262-017-0543-3 | |
|
Bharathi A, Naik D. Formulation and in vitro evaluation of chronotherapeutic press-coated tablets of valsartan with natural controlled released gums. Eur J Pharm Med Res, 2019; 6(4):480-7. | |
|
Chickpetty SM, Basawaraj R, Kulkarni RV. Natural polysaccharides-based compression coated tablets for colon targeted delivery of naproxen for the treatment of colitis. Pharm Lett, 2010; 2(6):114-23. | |
|
Dabhi C, Randale S, Belgamwar V, Gattani S, Tekade A. Predictable pulsatile release of tramadol hydrochloride for chronotherapeutics of arthritis. Drug Deliv, 2010; 17(5):273-81. https://doi.org/10.3109/10717541003706240 | |
|
D'Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, Senni M. Neprilysin inhibition in heart failure mechanisms and substrates | |
|
beyond modulating natriuretic peptides. Eur J Heart Fail, 2017; 19(6): 710-7. https://doi.org/10.1002/ejhf.799 | |
|
Dharmarajan K, Hsieh AF, Lin Z, Bueno H, Ross JS, Horwitz LI, Barreto-Filho JA, Kim N, Bernheim SM, Suter LG, Drye EE, Krumholz HM. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. J Am Med Assoc, 2013; 309(4):355-63. https://doi.org/10.1001/jama.2012.216476 | |
|
Feng L, Godtfredsen SE, Karpinski P, Sutton PA, Prashad M, Girgis MJ, Hu B, Liu Y, Blacklock TJ, Novartis AG. Pharmaceutical combinations of an angiotensin receptor antagonist and a nep inhibitor. Canada Patent CA2590511A1.2007-05-18. | |
|
Feng L, Karpinski PH, Sutton P, Liu Y, Hook DF, Hu B, Blacklock TJ, Fanwick PE, Prashad M, Godtfredsen S, Ziltener C. LCZ696: a dual-acting sodium supramolecular complex. Tetrahedron Lett, 2012; 53(3):275-6. https://doi.org/10.1016/j.tetlet.2011.11.029 | |
|
Gami AS, Howard DE, Olson EJ, Somers VK. Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med, 2005; 352(12):1206-14. https://doi.org/10.1056/NEJMoa041832 | |
|
Gunsel WC. Compression-coated and layer tablets, in pharmaceutical dosage forms: tablets. In: Lieberman HA, Lachman L (Eds.). Marcel Dekker, New York, NY, vol. 1, pp 187-224, 1980. | |
|
Hermida RC, Ayala DE, Mojón A, Fernandez JR. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol, 2011; 22(12):2313-21. https://doi.org/10.1681/ASN.2011040361 | |
|
aIndian Pharmacopoeia, Govt of India, Ministry of Health and Family Welfare, IPC, Ghaziabad, India, 2018a; 2.5.5:309. | |
|
Indian Pharmacopoeia, Govt of India. Ministry of Health and Family Welfare, IPC, Ghaziabad, India, vol. 2.5.3, p 308, 2018b. | |
|
Indian Pharmacopoeia, Govt of India. Ministry of Health and Family Welfare, IPC, Ghaziabad, India, vol. 2, p 1118, 2018c. | |
|
Indian Pharmacopoeia, Govt of India. Ministry of Health and Family Welfare, IPC, Ghaziabad, India, vol. 2.5.1, p 299-302, 2018d. | |
|
International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines on "Stability testing of active pharmaceutical ingredients and finished pharmaceutical products" Annex 10. WHO Technical Reports Series, No. 1010, 2018. Available via https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1ar2-stability-testing-new-drug-substances-and-products (Accessed 24 August 2019) | |
|
https://www.who.int/publications/m/item/stability-testing-of-active-pharmaceutical-ingredients-and-finished-pharmaceutical-products-stability-conditions-for-who-member-states-by-region- (Accessed 09 March 2021) | |
|
Kobalava Z, Kotovskaya Y, Averkov O, Pavlikova E, Moiseev V, Albrecht D, Chandra P, Ayalasomayajula S, Prescott MF, Pal P, Langenickel TH, Jordaan P, Rajman I. Pharmacodynamic and pharmacokinetic profiles of sacubitril/valsartan (LCZ696) in patients with heart failure and reduced ejection fraction. Cardiovasc Ther, 2016; 34(4):191-8. https://doi.org/10.1111/1755-5922.12183 | |
|
Koizumi K, Watanabe Y, Monita K, Utosuchi N. New method of preparing high porosity rapidly saliva soluble compressed tablets using mannitol with camphor, a subliming material. Int J Pharm, 1997; 152: 127-31. https://doi.org/10.1016/S0378-5173(97)04924-7 | |
|
Latha K, Srikanth VV, Sunil SA, Srinivasa NR, Uhumwangho MU, Shaik NB, Ramana Murthy KV. Applicability of gum karaya in the preparation and in vitro evaluation of losartan potassium as chronotherapeutic drug delivery system. J Sci Res, 2015; 7(1-2):65-74. https://doi.org/10.3329/jsr.v7i1-2.21182 | |
|
Li R, Pan Y, Chen D, Xu X, Yan G, Fan T. Design, preparation and in vitro evaluation of core-shell fused deposition modelling 3D-printed verapamil hydrochloride pulsatile tablets. Pharmaceutics, 2022; 14(2):437. https://doi.org/10.3390/pharmaceutics14020437 | |
|
Liu XJ, Zhang Y, Wang XZ. Study on co-crystallization of LCZ696 using in situ ATR-FTIR and imaging. Crystals, 2020; 10(10):922. https://doi.org/10.3390/cryst10100922 | |
|
Lopes CM, Lobo JMS, Pinto JF, Costa P. Compressed mini-tablet as a biphasic drug delivery system. Int J Pharm, 2006; 323(1-2):93-100. https://doi.org/10.1016/j.ijpharm.2006.05.063 | |
|
Muller JE, Stone H, Turi ZG, Rutherford JD, Czeisler CA, Parker C, Poole WK, Passamani E, Roberts R, Robertson T. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med, 1985; 313(21):1315-22. https://doi.org/10.1056/NEJM198511213132103 | |
|
Novartis Entresto granted expanded indication in chronic heart failure by FDA. 2021. Available via https://www.novartis.com/news/media-releases/Novartis Entresto granted expanded indication in chronic heart failure by FDA. (Accessed 16 April 2021) | |
|
Odeku OA, Fell JT. In-vitro evaluation of khaya and albizia gums as compression coatings for drug targeting to the colon. J Pharm Pharmacol, 2005; 57(2):163-8. https://doi.org/10.1211/0022357055362 | |
|
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J, 2016; 37(27):2129-200. https://doi.org/10.1093/eurheartj/ehw128 | |
|
Puri V, Sharma A, Kumar P, Singh I, Huanbutta K. Synthesis and characterization of Thiolated Gum Ghatti as a novel excipient: development of compression-coated mucoadhesive tablets of domperidone. ACS Omega, 2021; 6(24):15844-54. https://doi.org/10.1021/acsomega.1c01328 | |
|
Ross AC, Macrae RJ, Walther M, Stevens HN. Chronopharmaceutical drug delivery from a pulsatile capsule device based on programmable erosion. JPP, 2000; 52(8):903-9. https://doi.org/10.1211/0022357001774787 | |
|
Shim CY. Heart failure with preserved ejection fraction: the major unmet need in cardiology. Korean Circ J, 2020; 50(12):1051-61. https://doi.org/10.4070/kcj.2020.0338 | |
|
Smolensky MH, Portaluppi F. Chronopharmacology and chronotherapy of cardiovascular medications: relevance to prevention and treatment of coronary heart disease. Am Heart J, 1999; 137(42):S14-24. https://doi.org/10.1016/S0002-8703(99)70392-3 | |
|
Solomon SD, McMurray JV, Anand I, Ge J, Lam P, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen D, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zou J, Rizkala R, Gong J, Shi C, Lefkowitz MP, PARAGON-HF Investigators and Committees. Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med, 2019; 381(17):1609-20. https://doi.org/10.1056/NEJMoa1908655 | |
|
Songa AS, Meka VS, Nali SR, Kolapalli VR. An in vitro and in vivo investigation into the suitability of compression coated tablets of indomethacin for the treatment of rheumatoid arthritis which follow circadian rhythms. Drug Dev Ind Pharm, 2013; 39(3):447-56 https://doi.org/10.3109/03639045.2012.662509 | |
|
Singh S, Shyale SS, Karade P. Formulation and evaluation of orally disintegrating tablets of lamotrigine. Int J Pharm Sci Nanotechnol, 2015; 8(2):2881-8. https://doi.org/10.37285/ijpsn.2015.8.2.11 | |
|
Stevens H, MacDougal F. Controlled onset oral drug delivery: an opportunity for innovative life cycle management. American Pharmaceutical Review, 2014. Available via https://www.americanpharmaceuticalreview. com/Featured-Articles/163671-Controlled-Onset-Oral-Drug-Delivery-An- Opportunity-for-Innovative-Life-Cycle-Management/ (Accessed 19 June 2019) | |
|
Sunil SA, Srikanth MV, Rao NS, Murthy KV. Chronotherapeutic drug delivery from indomethacin compression coated tablets for early morning pain associated rheumatoid arthritis. Curr Drug Deliv, 2013; 10(1):109-21. https://doi.org/10.2174/1567201811310010017 | |
|
USFDA Dissolution testing methods. Available via https://www. accessdata.fda.gov/scripts/cder/dissolution/dsp_getalldata.cfm (Accessed 24 October 2019) | |
|
Vemula SK, Bontha VK. Colon targeted guar gum compression coated tablets of flurbiprofen: formulation, development and pharmacokinetics. Biomed Res Int, 2013; 2013(6):287919; https://doi. org/10.1155/2013/287919 https://doi.org/10.1155/2013/287919 | |
|
Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway W, Carson AP, Chamberlain AM, Chang R, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan S, Kissela BM, Knutson L, Kwan TW, Lackland T, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran E, Mussolino ME, Perak AM, Rosamond D, Roth GA, ampson KA, Satou GM, Schroeder EB, Shah SH, Shay M, Spartano NL, Stokes A, Tirschwell L, VanWagner LB and Tsao CW. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2020 update: a report from the American heart association. Circulation, 2020; 141(9):e139-596. https://doi.org/10.1161/CIR.0000000000000757 | |
|
Volpe M, Gallo G. Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike? Eur Heart J, 2021; 42(36):3753-5. https://doi.org/10.1093/eurheartj/ehab489 | |